Appearance of new anticancer agents with excellent effect for chemotherapy of cancer is rare. Consequently, clinicians must develop a better method of administration using the existing anticancer drugs. One of such methods is the combination of multidrugs, which is extensively being employed in clinics. We have also used a two-drug combination therapy with mitomycin-C (MMC) and 5-fluorouracil (5-FU), and other combinations (Nakao et al. 1972; Kubo et al. 1974) . In the present series of work, we have performed an examination of a threedrug combination therapy with MMC, 5-FU and a newly developed, water-soluble nitrosourea derivative, (4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU).
ACNU is a nitrosourea derivative synthesized by Arakawa et al. (1974) , and is characterized by its solubility in water, while other nitrosourea derivatives are liposoluble. Its antitumor activity has been recognized by Arakawa and Shimizu on leukemia L1210, myeloid leukemia C-1498, plasma cell tumor X5563, Ehrlich carcinoma, mammary tumor MM102 and FN3A, meningeal sarcoma MS-147, lymphoma LS-1, as well as in rat ascites hepatoma AH-130 and AH-44 (Arakawa et al. 1974; Ichiunura 1975; Shimizu and Arakawa 1975 Table 2 shows the results of 14 cases of MFU-I-O therapy. Effective cases of I-A or over were 5 of 14 cases (36%), consisting of 2 cases of stomach cancer and 1 case each of intestinal, lung, and uterine cancer. Histologically, they were adeno carcinoma, with the exception of lung cancer which was undifferentiated small cell carcinoma. Since the introduction of ACNU into clinics, its phase I study has been carried out in various institutions and organizations in Japan; the results were reported as the total assessement (Cooperative study group of phase I study on ACNU, 1976). Later the phase II study has been carried out, and effectivness of ACNU has been reported for esophageal cancer (Yamagata et al. 1977 (Saito et al. 1977) , metastatic lung tumor (Saijo et al. 1977) , and malignant lymphoma (Majima et al. 1978) .
In Europe and USA, the phase II study has already been completed for three nitrosourea derivatives, BCNU, CCNU, and methyl-CCNU , which were recognized as effective for brain tumor and Hodgkin's disease , though there was a slight difference among individual agents, and an extensive antitumor effect has been seen in non-Hodgkin's lymphoma , melanoma, lung carcinoma, stomach cancer, colon cancer, head-and-neck cancer, breast cancer , uterine cervical cancer, and ovarian cancer (Carter et al. 1972; Wasserman et al . 1974a Wasserman et al . , b, 1975 Slavik 1976 ). These agents are being used as a part of combination therapy and the results are accumulating.
With regard to ACNU, both fundamental (Kato et al . 1976 
